Guardant Health, Inc. (GH) Key Metrics
GH valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $21.28B
- Enterprise value
- $24.42B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 18.0 10-yr median 20.1
- Price / book
- 55.7 10-yr median 12.7
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.58
GH key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsGH valuation Price multiples at each fiscal year-end price.
Price / sales+157.0%
13.0
2025 · hover or tap a bar for each year
20162025
Free cash flow yield+5.5 pts
−1.8%
2025 · hover or tap a bar for each year
20162025
GH returns How much profit the business earns on the capital it uses.
Return on invested capital+9.9 pts
−90.2%
2025 · hover or tap a bar for each year
20162025
Return on assets+2.9 pts
−23.8%
2025 · hover or tap a bar for each year
20162025
Free cash flow margin+13.5 pts
−23.7%
2025 · hover or tap a bar for each year
20162025
Asset turnover+24.3%
0.56
2025 · hover or tap a bar for each year
20162025
GH per-share figures Results divided by the shares outstanding at year-end.
Revenue per share+30.1%
$7.83
2025 · hover or tap a bar for each year
20162025
Earnings per share
−$3.32
2025 · hover or tap a bar for each year
20162025
Free cash flow per share
−$1.86
2025 · hover or tap a bar for each year
20162025
Book value per share
−$0.79
2025 · hover or tap a bar for each year
20162025
Shares outstanding+2.1%
125.4M
2025 · hover or tap a bar for each year
20162025
GH financial health Debt, liquidity and how easily interest is covered.
Net debt+$12.5M
$508.5M
2025 · hover or tap a bar for each year
20162025
Current ratio+3.5%
4.84
2025 · hover or tap a bar for each year
20162025
Interest coverage
-112.2
2025 · hover or tap a bar for each year
20162025
Debt / assets−5.6%
0.85
2025 · hover or tap a bar for each year
20162025
GH efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding−3 days
46 days
2025 · hover or tap a bar for each year
20162025
Days of inventory−2 days
82 days
2025 · hover or tap a bar for each year
20162025
Days payables outstanding−8 days
49 days
2025 · hover or tap a bar for each year
20162025
Cash conversion cycle+3 days
80 days
2025 · hover or tap a bar for each year
20162025
Capex / revenue+0.2 pts
4.9%
2025 · hover or tap a bar for each year
20162025
GH valuation history
Fiscal year-endToday10-year median
GH returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
GH debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
GH cash returned to shareholders
DividendsBuybacksFree cash flow
GH price vs earnings per share
Share price at year-endEPS (right axis)
GH key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $12.81B | $3.75B | $3.03B | $2.78B | $10.13B | $12.57B | $7.08B | $3.20B | — | — |
| Enterprise value | $13.31B | $4.25B | $3.21B | $3.14B | $10.57B | $11.63B | $6.60B | $2.78B | — | — |
| Price / sales | 13.0 | 5.1 | 5.4 | 6.2 | 27.1 | 43.8 | 33.0 | 35.3 | — | — |
| Price / book | — | — | 19.1 | 46.2 | 15.7 | 9.7 | 8.9 | 6.6 | — | — |
| EV / sales | 13.6 | 5.7 | 5.7 | 7.0 | 28.3 | 40.5 | 30.8 | 30.6 | — | — |
| Earnings yield | −3.3% | −11.6% | −15.8% | −23.6% | −4.0% | −2.0% | −1.1% | −2.7% | — | — |
| Free cash flow yield | −1.8% | −7.3% | −11.4% | −13.9% | −2.8% | −1.3% | −1.0% | −2.9% | — | — |
| Dividend yield | — | — | — | — | 0.2% | 0.1% | — | 0.1% | — | — |
| Shareholder yield (dividends + buybacks) | 0.4% | 0.0% | 0.0% | 0.3% | 1.0% | 0.1% | 0.0% | 0.1% | — | — |
| Share price at fiscal year-end | $102.14 | $30.55 | $27.05 | $27.20 | $100.02 | $128.88 | $78.14 | $37.59 | — | — |
| Per share | ||||||||||
| Revenue per share | $7.83 | $6.02 | $5.04 | $4.40 | $3.69 | $2.94 | $2.37 | $1.07 | $0.70 | — |
| Earnings per share | −$3.32 | −$3.56 | −$4.28 | −$6.41 | −$4.00 | −$2.60 | −$0.84 | −$1.00 | −$1.18 | — |
| Operating cash flow per share | −$1.47 | −$1.95 | −$2.90 | −$3.03 | −$2.06 | −$1.07 | −$0.52 | −$0.85 | −$1.02 | — |
| Free cash flow per share | −$1.86 | −$2.24 | −$3.08 | −$3.79 | −$2.80 | −$1.62 | −$0.76 | −$1.09 | −$1.15 | — |
| Cash per share | $9.58 | $6.84 | $10.44 | $9.90 | $9.21 | $18.41 | $5.77 | $4.93 | $3.13 | — |
| Book value per share | −$0.79 | −$1.14 | $1.42 | $0.59 | $6.37 | $13.32 | $8.81 | $5.68 | $4.36 | — |
| Tangible book value per share | −$1.62 | −$1.22 | $1.31 | $0.44 | $6.19 | $13.12 | $8.61 | $5.59 | $4.24 | — |
| Dividends per share | — | — | — | — | $0.18 | $0.07 | — | $0.04 | — | — |
| Capex per share | $0.39 | $0.29 | $0.18 | $0.76 | $0.74 | $0.55 | $0.23 | $0.24 | $0.13 | — |
| Debt per share | $13.64 | $10.88 | $12.09 | $13.40 | $13.56 | $8.76 | $0.45 | $0.00 | $0.01 | — |
| Shares outstanding | 125.4M | 122.7M | 112.0M | 102.2M | 101.3M | 97.5M | 90.6M | 85.0M | 70.7M | — |
| Change in shares outstanding | +2.1% | +9.6% | +9.6% | +0.9% | +3.9% | +7.6% | +6.5% | +20.2% | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | — | — | −438.1% | −185.7% | −41.7% | −24.2% | −11.8% | −21.5% | −42.9% | −57.9% |
| Return on invested capital (ROIC) | −90.2% | −100.1% | −117.1% | −57.2% | −45.0% | −59.8% | −34.2% | −96.4% | −135.4% | — |
| Return on assets (ROA) | −23.8% | −26.7% | −28.2% | −34.3% | −18.1% | −15.7% | −9.8% | −18.3% | −36.2% | −39.6% |
| Return on tangible assets | −21.8% | −29.6% | −27.0% | −41.0% | −18.5% | −11.3% | −8.0% | −14.7% | −24.9% | −39.6% |
| Free cash flow margin | −23.7% | −37.2% | −61.3% | −86.1% | −76.0% | −55.1% | −31.9% | −101.9% | −163.0% | −152.4% |
| Financial health | ||||||||||
| Total debt | $1.71B | $1.34B | $1.35B | $1.37B | $1.37B | $854.5M | $40.4M | $216,000 | $659,000 | $17.0M |
| Cash & short-term investments | $1.20B | $840.0M | $1.17B | $1.01B | $932.7M | $1.79B | $522.8M | $419.0M | $221.3M | $95.3M |
| Net debt | $508.5M | $496.1M | $185.1M | $358.1M | $441.0M | −$940.4M | −$482.4M | −$418.7M | −$220.7M | −$78.2M |
| Debt / equity | — | — | 8.53 | 22.75 | 2.13 | 0.66 | 0.05 | 0.00 | 0.00 | 0.21 |
| Debt / assets | 0.85 | 0.90 | 0.76 | 0.85 | 0.62 | 0.38 | 0.04 | 0.00 | 0.00 | 0.15 |
| Current ratio | 4.84 | 4.68 | 6.54 | 6.17 | 5.72 | 28.27 | 8.21 | 9.99 | 12.38 | 7.22 |
| Quick ratio | 4.56 | 4.36 | 6.24 | 5.90 | 5.57 | 27.93 | 8.00 | 9.80 | 12.01 | 7.03 |
| Interest coverage | -112.2 | -171.9 | -219.1 | -211.2 | -159.5 | -53.5 | -69.7 | -74.3 | -28.4 | -14.5 |
| Working capital | $1.16B | $829.5M | $1.14B | $998.4M | $919.4M | $1.82B | $524.6M | $422.0M | $223.3M | $88.8M |
| Invested capital | $409.2M | $356.4M | $343.8M | $418.2M | $1.09B | $358.1M | $316.0M | $64.4M | $87.9M | $1.5M |
| Tangible asset value | −$202.5M | −$149.7M | $146.4M | $45.2M | $627.5M | $1.34B | $829.3M | $517.2M | $299.9M | $79.7M |
| Net current asset value | −$646.9M | −$570.1M | −$280.6M | −$358.2M | −$445.4M | $972.2M | $482.8M | $406.5M | $208.6M | $66.2M |
| Graham net-net per share | −$6.10 | −$5.43 | −$3.23 | −$4.30 | −$5.31 | $9.54 | $4.99 | $4.56 | $2.83 | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | $17.9M | $7.1M | — | $3.2M | — | — |
| Share buybacks (net) | $45.0M | $0 | $0 | $7.9M | $83.8M | $0 | $723,000 | $172,000 | $7.2M | $100,000 |
| Capex / revenue | 4.9% | 4.7% | 3.6% | 17.2% | 20.1% | 18.9% | 9.9% | 22.3% | 18.0% | 7.0% |
| Capex / depreciation | 1.22 | 0.83 | 0.48 | 2.15 | 3.37 | 3.37 | 1.87 | 2.83 | 1.73 | 0.48 |
| Stock-based compensation / revenue | 16.9% | 19.0% | 16.1% | 21.1% | 40.5% | 50.3% | 7.9% | 7.6% | 7.4% | 7.8% |
| R&D / revenue | 37.1% | 47.1% | 65.1% | 83.2% | 70.4% | 52.3% | 40.3% | 56.0% | 51.3% | 43.0% |
| SG&A / revenue | 71.9% | 73.8% | 80.0% | 103.2% | 106.7% | 104.4% | 65.2% | 98.9% | 139.0% | 143.0% |
| Efficiency | ||||||||||
| Days sales outstanding | 46.1 | 49.2 | 60.2 | 79.1 | 73.7 | 64.5 | 71.2 | 97.6 | 59.6 | 50.5 |
| Days of inventory on hand | 82.1 | 83.8 | 91.3 | 96.0 | 79.3 | 74.7 | 62.8 | 69.4 | 58.0 | 45.7 |
| Days payables outstanding | 48.6 | 56.9 | 97.0 | 125.4 | 68.1 | 46.4 | 69.3 | 66.1 | 47.1 | 52.1 |
| Cash conversion cycle (days) | 79.6 | 76.1 | 54.5 | 49.8 | 84.9 | 92.8 | 64.7 | 100.9 | 70.6 | 44.1 |
| Receivables turnover | 7.92 | 7.43 | 6.06 | 4.61 | 4.95 | 5.66 | 5.12 | 3.74 | 6.12 | 7.22 |
| Payables turnover | 7.51 | 6.42 | 3.76 | 2.91 | 5.36 | 7.86 | 5.27 | 5.53 | 7.75 | 7.01 |
| Inventory turnover | 4.45 | 4.36 | 4.00 | 3.80 | 4.60 | 4.88 | 5.82 | 5.26 | 6.29 | 7.99 |
| Asset turnover | 0.56 | 0.45 | 0.33 | 0.24 | 0.17 | 0.18 | 0.28 | 0.19 | 0.22 | 0.22 |
| Average receivables | $124.1M | $99.5M | $93.0M | $97.5M | $75.5M | $50.6M | $41.8M | $24.2M | $8.1M | $3.5M |
| Average payables | $46.5M | $45.1M | $60.3M | $53.7M | $22.9M | $11.8M | $13.4M | $7.8M | $4.1M | $3.2M |
| Average inventory | $78.5M | $66.5M | $56.8M | $41.1M | $26.7M | $18.9M | $12.2M | $8.2M | $5.0M | $2.8M |
| Intangibles / total assets | 5.1% | 0.7% | 0.7% | 0.9% | 0.8% | 0.9% | 1.9% | 1.3% | 2.5% | 0.0% |
Computed from GH's annual financial statements (latest annual report filed February 19, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
GH valuation and financial ratios
Guardant Health earned a return on invested capital of −90.2% in fiscal 2025. It ended the year with $1.7 billion of debt and $1.2 billion in cash and short-term investments, net debt of $508.5 million. It returned $45.0 million to shareholders: $0 in dividends and $45.0 million in share buybacks.
See the GH income statement, the GH chart for price history, or the GH stock overview for the latest quote and news.
GH key metrics FAQ
What is Guardant Health's ROIC?
Guardant Health's return on invested capital was −90.2% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Guardant Health have?
Guardant Health had total debt of $1.7 billion at the end of fiscal 2025.
Does Guardant Health buy back its shares?
Yes. Guardant Health spent $45.0 million on net share repurchases in fiscal 2025 Shares outstanding changed +2.1% over the year, to 125.4M..
What is Guardant Health's free cash flow yield?
Guardant Health generated -$233.1 million of free cash flow in fiscal 2025, a free cash flow yield of −1.8% on its market value at year-end ($12.8 billion).
What is Guardant Health's current ratio?
Guardant Health's current ratio was 4.84 at the end of fiscal 2025: current assets were 4.84 times current liabilities.